Annual CFF
$84.99 M
+$14.64 M+20.81%
December 31, 2023
Summary
- As of February 8, 2025, ANTX annual cash flow from financing activities is $84.99 million, with the most recent change of +$14.64 million (+20.81%) on December 31, 2023.
- During the last 3 years, ANTX annual CFF has risen by +$81.16 million (+2115.69%).
- ANTX annual CFF is now at all-time high.
Performance
ANTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$23.00 K
+$23.00 K+100.00%
September 30, 2024
Summary
- As of February 8, 2025, ANTX quarterly cash flow from financing activities is $23.00 thousand, with the most recent change of +$23.00 thousand (+100.00%) on September 30, 2024.
- Over the past year, ANTX quarterly CFF has dropped by -$326.00 thousand (-93.41%).
- ANTX quarterly CFF is now -99.97% below its all-time high of $79.74 million, reached on March 31, 2021.
Performance
ANTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$51.00 K
-$66.04 M-99.92%
September 30, 2024
Summary
- As of February 8, 2025, ANTX TTM cash flow from financing activities is $51.00 thousand, with the most recent change of -$66.04 million (-99.92%) on September 30, 2024.
- Over the past year, ANTX TTM CFF has dropped by -$85.09 million (-99.94%).
- ANTX TTM CFF is now -99.94% below its all-time high of $85.31 million, reached on September 30, 2023.
Performance
ANTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ANTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +20.8% | -93.4% | -99.9% |
| 3 y3 years | +2115.7% | -93.4% | -99.9% |
| 5 y5 years | +2115.7% | -93.4% | -99.9% |
ANTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +20.8% | -100.0% | +102.4% | -99.9% | at low |
| 5 y | 5-year | at high | +2115.7% | -100.0% | +102.4% | -99.9% | at low |
| alltime | all time | at high | +2115.7% | -100.0% | +102.4% | -99.9% | at low |
AN2 Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $23.00 K(>+9900.0%) | $51.00 K(-99.9%) |
| Jun 2024 | - | $0.00(-100.0%) | $66.09 M(-22.4%) |
| Mar 2024 | - | $349.00 K(-208.7%) | $85.14 M(+0.2%) |
| Dec 2023 | $84.99 M(+20.8%) | -$321.00 K(-100.5%) | $84.99 M(-0.4%) |
| Sep 2023 | - | $66.07 M(+246.8%) | $85.31 M(+343.4%) |
| Jun 2023 | - | $19.05 M(+9472.9%) | $19.24 M(+161.2%) |
| Mar 2023 | - | $199.00 K(>+9900.0%) | $7.37 M(-89.5%) |
| Dec 2022 | $70.36 M | $0.00(-100.0%) | $70.36 M(+1.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2022 | - | -$10.00 K(-100.1%) | $69.39 M(+0.3%) |
| Jun 2022 | - | $7.18 M(-88.6%) | $69.16 M(+11.6%) |
| Mar 2022 | - | $63.19 M(-6620.8%) | $61.98 M(-21.1%) |
| Dec 2021 | $78.53 M(+1947.3%) | - | - |
| Dec 2021 | - | -$969.00 K(+303.8%) | $78.53 M(-1.2%) |
| Sep 2021 | - | -$240.00 K(<-9900.0%) | $79.50 M(-0.3%) |
| Jun 2021 | - | $0.00(-100.0%) | $79.74 M(0.0%) |
| Mar 2021 | - | $79.74 M | $79.74 M |
| Dec 2020 | $3.84 M | - | - |
FAQ
- What is AN2 Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for AN2 Therapeutics?
- What is AN2 Therapeutics annual CFF year-on-year change?
- What is AN2 Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for AN2 Therapeutics?
- What is AN2 Therapeutics quarterly CFF year-on-year change?
- What is AN2 Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for AN2 Therapeutics?
- What is AN2 Therapeutics TTM CFF year-on-year change?
What is AN2 Therapeutics annual cash flow from financing activities?
The current annual CFF of ANTX is $84.99 M
What is the all time high annual CFF for AN2 Therapeutics?
AN2 Therapeutics all-time high annual cash flow from financing activities is $84.99 M
What is AN2 Therapeutics annual CFF year-on-year change?
Over the past year, ANTX annual cash flow from financing activities has changed by +$14.64 M (+20.81%)
What is AN2 Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ANTX is $23.00 K
What is the all time high quarterly CFF for AN2 Therapeutics?
AN2 Therapeutics all-time high quarterly cash flow from financing activities is $79.74 M
What is AN2 Therapeutics quarterly CFF year-on-year change?
Over the past year, ANTX quarterly cash flow from financing activities has changed by -$326.00 K (-93.41%)
What is AN2 Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ANTX is $51.00 K
What is the all time high TTM CFF for AN2 Therapeutics?
AN2 Therapeutics all-time high TTM cash flow from financing activities is $85.31 M
What is AN2 Therapeutics TTM CFF year-on-year change?
Over the past year, ANTX TTM cash flow from financing activities has changed by -$85.09 M (-99.94%)